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Synthesis and biological evaluation of new aryl-alkyl(alkenyl)-4-
benzylpiperidines, novel Sigma Receptor (SR) modulators, as potential 
anticancer-agent. 
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Abstract 
 
In the early 2000s, the Sigma Receptor (SR) family was identified as potential 
“druggable” target in cancer treatment. Indeed, high density of SRs was found in breast, 
lung, and prostate cancer cells, supporting the idea that SRs could play a role in tumor 
growth and progression. Moreover, a link between the degree of SR expression and 
tumor aggressiveness has been postulated, justified by the presence of SRs in high 
metastatic-potential cancer cells. As a consequence, considerable efforts have been 
devoted to the development of small molecules endowed with good affinity towards the 
two SR subtypes (S1R and S2R) with potential anticancer activity. Herein we report the 
synthesis and biological profile of aryl-alkyl(alkenyl)-4-benzylpiperidine derivatives - as 
novel potential anticancer drugs targeting SR. Among them, 3 (RC-106) exhibited a 
preclinical profile of antitumor efficacy on a panel of cell lines representative of different 
cancer types (i.e. Paca3, MDA-MB 231) expressing both SRs, and emerged as a hit 
compound of a new class of SRs modulators potentially useful for the treatment of cancer 
disease. 
 
Keywords 
Sigma Receptor (SR); pan-SR modulators; compound 3 (RC-106); S1R 
agonist/antagonist profile; potential anticancer property; apoptotic pathway. 
 
1. Introduction 
Sigma receptors (SRs) are an enigmatic receptor family localized in plasmatic, 
mitochondrial and endoplasmic reticulum membranes of several organs including liver, 
kidney and brain. Radioligand binding studies and biochemical analyses have shown the 
presence of two SR subtypes, Sigma 1 (S1R) and Sigma 2 (S2R) receptors with different 
anatomical distribution, distinct physiological and pharmacological profiles [1-4].  
It is well known that S1Rs play critical roles in the mammalian nervous system, indeed 
their involvement in different neurodegenerative and neuropsychiatric diseases has been 
well documented [5-8]. Their ligands can yield both cytoprotective or cytotoxic actions. 
In detail, S1R agonists promote neuroprotection, neurite outgrowth, trophic factor 
production as well as microglial activation, mitochondrial integrity and reduce production 
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of reactive oxygen species [9,10]. As a consequence, S1R agonists display a high 
therapeutic potential for Central Nervous System (CNS) pathologies such as 
Amyotrophic Lateral Sclerosis, Multiple Sclerosis, Alzheimer’s disease and Parkinson 
disease [5,11,12]. Conversely, S1R antagonists may play a role in neuropathic pain and 
anticancer therapy. Overexpression of S1R in high metastatic potential cancer cells, 
together with the efficacy of the S1R antagonist Rimcazole (Fig. 1) in inhibiting tumor 
cell survival and in promoting apoptosis in breast cancer cells (MCF-7, MDA-MB-231, 
MDA-MB-157 and T47D) suggests a link between the degree of S1R expression and 
tumor growth and aggressiveness [13]. Despite the evidence supporting the importance of 
S1R in cancer, the mechanism of action of S1R antagonists in causing cell death is still 
unclear. Currently, it has been hypothesized that the observed apoptototic phenomena are 
related to the increase of intracellular calcium levels [14-16]. 
The S2R subtype is still largely unknown: it has not been cloned yet and its molecular 
structure has not been clarified .  In the intracellular environment, S2R binding sites are 
localized in mitochondria, lysomes, endoplasmic reticulum, and plasma membrane. 
Recent studies describe how S2R ligands trigger a cell response which inhibit the activity 
of the P-glycoprotein, responsible for the active extrusion of anticancer drugs, leading to 
cell death. [17,18]. Moreover, the hypothesis of a correlation between S2R and 
Progesterone Receptor Membrane Component 1 (PGRMC1) [19,20] supports the idea 
that S2R may exert a critical role in tumorigenesis [18]. Indeed, the over-expression of 
PGRMC1 has been associated to tumor stage and to actively proliferating and invasive 
cancer cells [21]. It is also relevant that proliferating breast carcinoma cells express S2R 
up to ten times more than quiescent cells, and the degree of S2R
 
expression has been 
correlated with tumor staging and grading [22-24]. The highest level of S2R has been 
detected in pancreatic cancer cell lines (Panc-02, Panc-01, CFPAC-1, AsPC-1) [25]. A 
recent study, carried out on mouse breast cancer (EMT-6) and human melanoma (MDA-
MB-435) cell lines, demonstrate that siramesine (Fig. 1), a S2R selective ligand 
commonly used as reference compound, can induce cell death (with an EC50 in both cell 
lines lower than 10 µM) by three different mechanisms: caspase activation, autophagy, 
and impaired cell-cycle progression [26]. In the same work, it has been also demonstrated 
that other S2R ligands, i.e. SV119, WC-26 and RHM-138 (Fig. 1), possess a cytotoxic 
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effect in the micromolar range in the aforementioned cancer cell lines [26]. Moreover, the 
same compounds are able to inhibit proliferation of pancreatic cancer cells (human lines: 
BxPC3, AsPC1, Cfpac, Panc1 and PaCa-2; murine line: Panc02) with an IC50 ≤ 100 µM 
[25]. 
 
Fig. 1. S1R and S2R compounds able to promote antiproliferative effects. Rimcazole (KiS1 = 908.0 ± 
99 nM; KiS2 = 302.0 ± 37 nM) [27]. Siramesine (KiS1 = 17.0 nM; KiS2 = 0.12 nM); SV119 (KiS1 = 
1417.0 nM; KiS2 = 5.2 nM); WC-26 (KiS1 = 1436.5 ± 166.1 nM; KiS2 = 2.58 ± 0.59 nM); RHM-138 
(KiS1 = 544.0 nM; KiS2 = 12.3 nM); SW43 (KiS1 = 133.0 nM; KiS2 = 19.0 nM) [28]. 
 
On the bases of the above findings, we reasoned that both S1R antagonist and S2R 
agonists could be useful tools to address novel and more focused cancer treatments. 
Hence, SRs could represent an exciting target to develop anticancer drugs with novel 
mechanisms of action. Our group has previously prepared and characterized a wide series 
of compounds with preferential affinity towards S1R [29a-d]. In an intriguing 
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observation, we documented that the presence of the bulky 4-benzylpiperidine moiety, 
while preserving high binding strength for S1R, increases the affinity towards S2R [29c]. 
Therefore, in the present study we present our efforts aimed at the identification and 
characterization of potent SR
 
modulators, able to bind both receptor subtypes. 
Specifically, we report herein the preliminary structure-activity relationship (SAR) (Fig. 
2) of aryl-alkyl(alkenyl)-4-benzylpiperidines with the general structure of Fig. 2.  
Derivatives 3 and 6 that displayed good affinity toward both receptor subtypes, from now 
on called pan-SR ligands, were passed for testing in vitro cytotoxic activity evaluation. 
To validate the hypothesis that S1R and S2R modulators could be effective as anticancer 
drugs, compound 3  was next screened towards a panel of tumor cell lines representative 
of various cancer types, all expressing both sigma receptors. The results of our studies 
showed that 3, called by us RC-106,  has interesting anticancer activities against prostate, 
glioblastoma, pancreas and breast cancer cell lines. The activity against pancreatic PaCa3 
cells is of particular interest, being 3 (RC-106) effective against actively proliferating 
cells (IC50 = 42 µM) and against cells with reduced proliferation rate (IC50 = 7.0 µM,). 
The results of this effort are described below. 
 
 
Fig. 2. SAR exploration. Structural  elements subjected to variation are highlighted.  
 
2. Results 
2.1. Chemistry  
The preparation of compounds 1-12 is summarized in Scheme 1. In cases where a chiral 
center was present, (semi)preparative chiral chromatography was used to isolate the 
stereoisomers. 
The key intermediate of the synthetic process is the β-aminoketone A. The synthetic 
pathway to obtain A was already described by us and involves a Michael addition of 4-
benzylpiperidine to but-3-en-2-one in absolute ethanol and glacial acetic acid, followed 
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by purification via acid/basic extraction, as reported in our previous work [29c]. The 
subsequent lithiation reaction at aryl-bromine in anhydrous Et2O at -78 °C with t-butyl 
lithium, followed by addition/substitution reaction in the presence of the β-aminoketone 
A and quenching with H2O, led to isolate crude compounds. After purification via 
acid/basic extraction, 1 and 2 in sufficient amount for the subsequent reaction an suitable 
purity for biological assay were obtained, as confirmed by 1H-NMR, 13C-NMR and 
UPLC-MS analysis. 
 Scheme 1. Synthesis of compounds 1-12.  
 
Arylalkylaminoalcohols 1 and 2 were treated with trifluoroacetic anhydride in the 
presence of a catalytic amount of cupper triflate, according with a procedure already 
experimented by us [30]. In this way, compounds 3 and 4, as (E) stereoisomers C2-C3, 
together with low amounts of the olefinic regioisomers C3-C4, were obtained as 
evidenced by 1H-NMR. It is worth noting that no signals related to the (Z) stereoisomer, 
which represented the minor product using the standard acidic conditions (37% HCl) 
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[29b] were present in the 1H-NMR of crude products. As a further step, an amount of 
arylalkenylamines were subjected to catalytic reduction reaction in hydrogen atmosphere 
in the presence of Pd (0)/C 10% (p/p) in absolute EtOH, giving rise to the corresponding 
arylalkylamines 5 and 6. Crude 3-6 were purified using alumina (II Brockmann degree) 
column chromatography, yielding pure compounds as confirmed by 1H-NMR, 13C-NMR 
and UPLC-MS analysis. 
In the case of compounds bearing the hydroxyl group at the naphtylic moiety, an 
additional step was required, consisting in the protective reaction of the –OH group by t-
butyldimethylsilyl chloride, thus obtaining 7 which was lithiated in anhydrous THF at -78 
°C using an excess of n-butyl lithium. After 20 minutes, the aminoketone A was added to 
the C-lithiated intermediate, keeping the temperature below -50 °C for 1.5 h. The reaction 
was quenched with saturated aqueous NH4Cl and extracted with Et2O. The crude product 
was purified by column chromatography giving 8. An amount of this compound was 
subjected to an elimination reaction using trifluoroacetic anhydride in the presence of a 
catalytic amount of cupper triflate to give the arylalkenylamine 10 [(E) stereoisomer C2-
C3] as main compound, easily isolated by column chromatography. Compounds 8 and 10 
were then subjected to the deprotection of –OH-aromatic by drop wise addition of tetra-
N-butylammonium fluoride at 0 °C in argon atmosphere in anhydrous dichloromethane 
(DCM), to give 9 and 11, respectively. Lastly, the reduction reaction of 11 using a 
catalytic amount of Pd (0) in hydrogen atmosphere gave rise to arylalkylamine 12. With 
the exception of compound 11, which was purified by treatment with methanol, pure 9 
and 12 were obtained after purification through silica column chromatography. Also in 
the case of naphthol-derivatives 9 and 11-12, the identities were confirmed by 1H-NMR, 
13C-NMR and UPLC-MS analysis.  
All potential SR modulators 1-6, 9 and 11-12 were obtained in a sufficient amount and 
with the appropriate degree of purity for the subsequent biological investigations and, in 
the case of racemic compound, also for HPLC chiral resolution. 
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2.2. Chiral resolution 
To investigate the relationship between stereochemistry and receptor binding affinity, we 
prepared enantiomeric 1-2, 5-6, 9 and 12. On the bases of our previous experience, a 
direct chiral HPLC method of enantiomeric separation was applied, and the scaling up of 
the process was performed [31a-e]. Baseline separation of racemates was obtained using 
cellulose and amylose derived chiral stationary phases (Chiralcel OJ-H, Chiralpack IC 
and Chiralpack IA), under different elution conditions, including different mixtures of n-
heptane and polar modifiers (methanol, ethanol or 2-propanol) and alcohols (methanol, 
ethanol and 2-propanol). In all cases 0.1 % of diethylamine (DEA) was added to the 
mobile phase. Moreover, in the case of the Chiralpak IC, the analysis were carried out 
also in the presence of 0.3 % of trifluoroacetic acid (TFA), which improves enantiomer 
separations. The optimized analytical methods (Table 1, Fig. SI1, see Supplementary 
material) were suitably transferred to the (semi)preparative scale. In detail,  enantiomeric 
1, 2, 5 and 9 were resolved by a (semi)preparative Chiralcel OJ-H column, eluting with 
ethanol and 0.1 %  diethylamine (for the compound 1) or methanol and 0.1 %  
diethylamine (for the compounds 2, 5 and 9), whereas compounds 6 and 12 were resolved 
on (semi)preparative Chiralpak IA, using methanol and 0.1 % of diethylamine, in all 
cases eluting at a flow rate of 2.5 mL/min. The elution conditions applied provided a 
quick access to the desired enantiomers (Table 2) with enantiomeric excess over than 
95%, as evidenced by analytical control of the collected fractions , and in sufficient 
amount for preliminary biological assays.  
 
Table 1. Analytical chiral resolution of 1-2, 5-6, 9 and 12.  
Compound Column Eluent K1 K2 α Rs 
1 Chiralcel OJ-H A 1.03 1.63 1.58 3.25 
2 Chiralcel OJ-H B 1.24 1.80 1.45 4.05 
5 Chiralcel OJ-H B 3.98 4.80 1.21 2.46 
6 Chiralpak IA B 0.57 0.81 1.42 3.06 
9 Chiralcel OJ-H B 1.10 1.61 1.46 2.62 
12 Chiralpak IA B 0.96 1.27 1.32 2.49 
Eluent:  A (100% ethanol, 0.1 %  diethylamine); B (methanol 100%,  0.1 % diethylamine), flow rate: 1 
mL/min; detection UV at 220 (compounds 2 and 6) and at  254 nm (compounds 1, 5, 9 and 12).  
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Table 2. Chiroptical properties of enantiomeric 1-2, 5-6, 9 and 12. 
Compound [α]D20 (c% in MeOH) ee (%)a K  
1a + 40.5 (0.2) 96.0 1.03  
1b - 42.3 (0.2) 97.0 1.63 
2a + 10.5 (0.6) 99.9 1.24 
2b - 9.2 (0.6) 98.0 1.80 
5a + 6.1 (0.2) 95.0 3.98  
5b - 6.3 (0.2) 95.0 4.80 
6a + 8.2 (0.3) 99.9 0.57 
6b - 8.3 (0.3) 99.9  0.81 
9a + 24.2 (0.1) 99.9 1.10  
9b - 24.8 (0.1) 99.9 1.61 
12° + 11.8 (0.3) 99.9 0.96 
12b - 12.0 (0.3) 99.9 1.27 
a
 Determined by chiral HPLC under the analytical conditions reported in Table 1. 
 
 
2.3. SAR studies 
The S1R and S2R binding site affinities of the tested compounds were determined in 
competition experiments using radioligands. All compounds were tested on guinea pig 
brain and rat liver membranes obtained by homogenization, centrifugation, and washing 
of the respective tissues. Both S1R and S2R binding site assays were performed with 
[3H]-(+)-pentazocine as radioligand. The S2R binding values were evaluated using [3H]-
DTG was used as radioligand in the S2R assays. Compounds with high affinity were 
tested three times. For compounds with low SR affinity, only one measure was 
performed. The SR affinities of all compounds towards both S1R and S2R are presented 
in Table 3. 
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Table 3. Binding affinities towards S1R and S2R. Values are expressed as mean ± SEM of three 
experiments.  
  
Compound Ar R KiS1 ± SEM KiS2 ± SEM  
1 2-naphtyl OH 6.9 ± 2 62.5  
1a 2-naphtyl OH 10 ± 2 81 ± 35  
1b 2-naphtyl OH 11 ± 1 79 ± 21  
2 Phenyl OH 9.8 ± 4 57 ± 11  
2a Phenyl OH 27 ± 9 339a  
2b Phenyl OH 40 ± 4 240a  
3 2-naphtyl - 12 ± 5 22 ± 3  
4 Phenyl - 0.7 ± 1 47± 13   
5 2-naphtyl H 5.6 ± 3 144a  
5a 2-naphtyl H 6.0 ± 0.5 26± 9  
5b 2-naphtyl H 6.9 ± 1 98  
6  Phenyl H 2.1 ± 1 6.5 ± 3  
6a Phenyl H 2.9 ± 0.4 8.9 ± 2.1  
6b Phenyl H 3.0 ± 0.3 7.9 ± 1.9  
9 6-hydroxy naphtyl OH 27 ± 5 118a  
9a 6-hydroxy naphtyl OH 70 ± 21 68 ± 8  
9b 6-hydroxy naphtyl OH 62 ± 4 905a  
11 6-hydroxy naphtyl - 9.6 ± 3 305a  
12 6-hydroxy naphtyl H 59 ± 5 314a  
12a 6-hydroxy naphtyl H 35± 2 582a  
12b 6-hydroxy naphtyl H 13 ± 4 105a  
a Compounds with high affinity were tested three times. For compounds with low SR affinity (> 100 nM), 
only one measure was performed. 
  
All compounds, with the only exception of 9a, 9b and 12, showed an interesting affinity 
towards S1R (KiS1 ≤ 50 nM) and a good/modest affinity towards S2R, with the exception 
of compounds 2a, 2b, 9 and 12, which are weak S2R binders. Particularly, all the 
arylalkylaminoalcohols 1, 2 and 9 showed a preference affinity towards S1R and the first 
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eluted enantiomers exhibit a slight preferential interaction with the target, in accordance 
with our previous work [32]. Conversely, SRs do not show stereoselectivity towards the 
enantiomer of arylalkylamines, confirming our previous findings [31a-b]. Of particular 
interest are compounds 3 and 6 (racemic and enantiomeric), having a good affinity 
towards both S1R and S2R. 
 
To propose a molecular rationale for the experimental affinity of the new 4-
benzylpiperidine derivatives for the S1R, we used our validated three-dimensional model 
of the S1R [29d,31a-b,33-35]. We applied a consolidated simulation recipe based on free 
energy of binding (∆Gbind) estimation in the framework of the Molecular 
Mechanics/PoissonBoltzmann Surface Area (MM/PBSA) computational methodology 
(Tables SI1, see Supplementary material) [36]. Taking the naphthalene derivative 3 as a 
proof-of-concept, the analysis of the corresponding MD trajectory reveals that 4-benzyl-
piperidine moiety establishes a strong network of polar and hydrophobic interactions with 
the receptor. As shown in Fig. 3A and B, the piperidine nitrogen atom is engaged in the 
prototypical salt bridge with the carboxylic side chain of Asp126, while the aliphatic 
portion of the heterocycle together with the benzyl ring are perfectly encased in the 
hydrophobic S1R cavity lined by residues Ile128, Phe133, Tyr173 and Leu186. Finally, 
the naphthalene group of 3 performs stabilizing pi interactions with the side chains of 
Arg119 and Trp121.     
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Fig. 3. (A) 2D schematic representation of the identified interactions between the S1R 3D model and 3. (B) 
Zoomed view of SR1 in complex with 3. The compound is in atom colored sticks-and-balls (C, gray; N, 
blue). Hydrogen atoms, water molecules, ions, and counterions are not shown for clarity. A dashed black 
line highlights the salt bridge between the S1R D126 side chain and the piperidine nitrogen atom of 3. (C) 
Per-residue binding enthalpy (∆Hbind,res) decomposition for the S1R/3 complex. Only SR1 amino acids from 
positions 100 to 200 – most relevant to ligand binding - are shown for clarity. 
 
For each compound, a quantitative analysis of ligand/protein interactions was next 
performed via a per-residue deconvolution of the enthalpic contribution to binding (Fig. 
SI3, see Supplementary material). Taking again compound 3 as reference, Fig. 3C shows 
the resulting interaction spectrum. Substantially, the hydrophobic interactions of 3 with 
the side chains of residues Ile128, Phe133, Tyr173, and Leu186 contribute an overall 
stabilization term to binding equal to -3.25 kcal/mol, while the permanent salt bridge 
between the N-atom of 3 and the side chain of Asp126 (average dynamic length (ADL) = 
4.09 ± 0.04 Å) reflects in a stabilizing contribution of -1.87 kcal/mol. Finally, the 
important pi/pi and pi/cation interactions (established between the naphthyl ring of the 
molecule and the indole ring of Trp121 and the cationic side chain of Arg119, 
respectively) result in a strong enthalpic stabilization of -2.01kcal/mol.  
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To sum up, compounds 3 and both racemic and enantiomeric 6 revealed good affinity 
towards S1R, in agreement with the molecular modelling studies, together with a S2R 
affinity and therefore they have been selected for a deeper biological investigation.  
 
2.4. Quantification of SRs expression in cancer cell lines  
As stated in the introduction section, an appropriate modulation of both receptors could 
have a synergic effect in inducing tumor cell death. Therefore, the first step of our in 
depth biological investigation consisted in testing a panel of cancer cell lines 
representative of different human solid tumors (Table 4) for SRs expression [37-40]. In 
details, we determined the expression levels of mRNA of S1R and PGRMC1, considered 
as the S2R binding site, by Real Time RT- Polymerase Chain Reaction (RT-PCR). 
 
Table 4. Tumor cell lines expressing both SR selected for this study 
Cell line Origin Tumor source Morphology 
Capan-2 Pancreas Primary tumor Epithelial 
Paca3 Pancreas Primary tumor Epithelial 
CFPaC-1 Pancreas Metastatic site Epithelial 
SUM 159 Breast Primary tumor Epithelial 
MDA-MB 231 Breast Metastatic site Epithelial 
PC3 Prostate Metastatic site Epithelial 
LNCaP Prostate Metastatic site Epithelial 
U87 Glioblastoma Primary tumor Epithelial 
 
The expression values of S1R and PGRMC-1 in CFPAC-1 line are very similar as 
evidenced by western blot and related densitometric analysis showed in supplematary 
data (Fig. SI4) and for this reason were used as reference values (arbitrary set equal to 1) 
for Real Time RT-PCR evaluation of S1R or PGRMC-1 expression in the panel of cell 
line investigated. As shown in Fig. 4 the highest S1R mRNA expression levels were 
found in MDA-MB 231, LNCaP and PaCa3 cell lines, whereas PGRMC1 mRNA was 
found to be highly expressed in PC3, CAPAN-2, and PaCa3 cell lines, respectively.  
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Fig. 4. Relative Quantification (RQ) of the target genes SR1 and PGRMC1 RNA expression. The 
mRNA levels  were normalized to the endogenous reference genes GAPDH and HPRT, and quantified 
respect to the value of S1R or PGRMC-1 found  in CFPaC-1 cell line that was arbitrary set equal to 1 
(RQ=1). Values are the mean ± SD of three independent experiments. 
 
2.5. Preliminary biological evaluation of 3 and 6  
We perform a preliminary assessment of the anticancer potential of compounds 3 and 6, 
showing a good affinity towards SRs, on PaCa3 cells that express both SRs at high level, 
using siramesine, a well known commercial S2R agonist, and NE100, a S1R antagonist, 
as reference compounds [26,41]. The effect of compounds 3, 6, siramesine and NE100 on 
cell viability was evaluated by the MTS assay. Cell lines grown in a 10% serum-
containing medium were exposed to increasing concentrations of compounds (0.1 µM - 
100 µM) for 24 hours. Compound 3 showed an interesting cytotoxic activity, comparable 
to siramesine, whereas compounds 6 and NE100 exhibited a poor cytotoxic effect (Fig. 
5). Since fetal bovine serum (FBS) is enriched in a variety of growth factors and 
neurosteroids that may interfere and/or mask SR binding sites, the effect of compounds 3 
and 6 on PaCa3 was evaluated also in serum-free medium. Interestingly, the decrease of 
cell viability induced by 3 was enhanced by starvation conditions (IC50 = 49.8 ± 4.1 µM 
and IC50 = 7.0 ± 0.2 µM, respectively). A similar effect was observed for siramesine (IC50 
= 45.4 ± 2.0 µM in complete medium and IC50 = 6.0 ± 0.3 µM, in starvation condition). 
On the contrary, starvation conditions are irrelevant for the cytotoxic properties of 6 and 
NE100. 
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According to this data, compound 3, by now on called RC-106, was selected for further 
investigation. 
 
 
Fig. 5. Effect of different SR modulators. The cells were exposed to compounds NE100, Siramesine, 3 
(RC-106) and 6,  for 24 hours in  the presence or in the absence of 10% FBS. The viability of the cells was 
determined by MTS assay (mean ± SD of 3 independent experiments).  
 
2.6. S1R agonist/antagonist profile of compound 3 (RC-106)  
Considering that the anticancer activity of a S1R ligands is related to their antagonist 
profile [13], we investigated the profile of 3 (RC-106) by assessing its in vitro ability to 
modulate NGF-induced neurite outgrowth in PC12 cells. Indeed, S1R agonists are known 
to potentiate NGF-induced neurite outgrowth when used in the low micromolar 
concentration range [29c,31a]. In detail, PC12 cells were incubated in a medium 
containing 0.5% FBS plus NGF (2.5 ng/ml), in the presence of increasing concentrations 
of 3 (RC-106) (0-10µM) for 96 h. Subsequently, cells were fixed and those displaying a 
neurite longer than the diameter of the cell body were counted. Neurite outgrowth was 
not affected by the addition of 3 (RC-106) up to 1 µM concentration; on the other hand, 
starting from 2.5 µM neurite outgrowth was completely inhibited (Fig. SI3, see 
Supplementary material), thus suggesting a S1R antagonist profile. To confirm this 
hypothesis, competition assays were performed. Specifically, PC12 cells were incubated 
with the standard S1R agonist PRE-084 (5, 10 and 25µM) in the absence/presence of 3 
(RC-106) at 0.25 or 2.5 µM. At 0.25 µM concentration, compound 3 (RC-106) 
significantly antagonized the effect of PRE-084 (10 and 25 µM) on NGF-induced neurite 
outgrowth (Fig. 6). At 2.5 µM concentration, 3 (RC-106) completely blocked NGF-
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induced neurite sprouting, even in the presence of PRE-084 (results not shown). The 
results confirm that 3 (RC-106) is a S1R antagonist. 
 
 
Fig. 6. Assay of NGF–induced neurite outgrowth in PC12 cells. Effect of PRE-084 alone or in 
combination with  3 (RC-106), at 0.25 µM. Histograms represent the mean±sem of at least 5 different 
experiments performed in triplicate. **= p<0.005; ***=p<0.0008; ****=p<0.000004 vs control (0 PRE-
084). °°=p<0.007; °°°=p<0.00004 vs PRE-084 10µM and  § = p<0.004 vs PRE-084 25µM. 
 
2.7. Effect of 3 (RC-106) on cell viability  
The cytotoxic acititvity of the pan-SR modulator 3 (RC-106) was evaluated by the MTS 
assay on the panel of cancer cell lines (LNCaP, PC3, U87, Paca3, Capan-2, MDA MB 
231, SUM 159) expressing both S1R and S2R. Briefly, cell lines grown in a 10% serum-
containing medium were exposed to increasing concentrations of 3 (RC-106) (0.1 µM - 
100 µM) for 24 hours (Fig. 7). Compound 3 (RC-106) induced a decrease of cell viability 
in all cell lines starting at 25 µM, with IC50 values ranging from 50 µM to 64 µM. The 
IC50 values did not vary significantly by increasing the incubation time up to 48 h, except 
for the Paca3 cell line, whose IC50 value markedly decreased after 48 h incubation (28.73 
± 4.6, data not shown).  
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Fig. 7. Effect of 3 (RC-106) on cell viability was evaluated on a panel of cancer cell lines with 
different histotypes. Cells were exposed to the drug for 24 hours in a 10% FBS containing medium. Cell 
viability was determined by the MTS assay (average of three independent experiments ± SD). 
 
The effect of 3 (RC-106) on U87, Capan-2 and LNCaP cancer cells in the absence of 
serum-induced cell cycle stimulation was also evaluated. Interestingly, in all the cell lines 
treated with 3 (RC-106) in serum-free conditions, a marked decrease of cell survival at 
low compound 3 (RC-106) concentrations compared to cells treated in FBS containing 
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medium, was shown, as evidenced by the low IC50 values (9.6 -10.5 µM) (Fig. 8). This 
trend is similar to that already evidenced on PaCa3 cells. 
 
 
Fig. 8. MTS assay in serum-free conditions. After a 24 hours starvation, cell lines were treated for 24 
hours with the indicated concentrations of 3 (RC-106). Data are expresses as percent of control values ± 
standard deviation. 
 
2.8. Study of 3 (RC-106) apoptotic pathway through capase 3 activation  
Lastly, to evaluate whether the observed decrease of cell viability under both conditions 
was due to apoptosis, TUNEL and Annexin V stainings (analyzed by FACS) and caspase 
3 activation (western blot, WB) were performed on PaCa3 cells, the tumor line displaying 
also the highest PGRMC1 mRNA levels. Moreover, according to Zeng C. et al. [42] we 
adopted caspase 3 assay in order to clarify the S2R agonist/antagonist profile of 3 (RC-
106). 
The TUNEL assay showed that in serum containing medium a significant induction of 
apoptosis after 24 h exposure to 3 (RC-106) could be observed only at 25 µM 
concentration (Fig. 9A).  This result is supported by the detection of the cleaved form of 
caspase 3 by WB analysis (Fig. 9C) and by the Annexin V assay. In these FACS 
experiments, a significant increase of early and late apoptotic cells (43.1% ± 3.4 and 
34.1% ± 8.2, respectively) at 25 µM compound 3 (RC-106) was detected (Fig. 9B).  
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Fig. 9. Apoptosis and apoptotic-related markers analysis in Paca3 cells grown in 10% FBS  complete 
medium. (A) TUNEL assay. Percentage of apoptotic cells after 24 h exposure to compound 3 (RC-106)  at 
10, 25 and 50 µM. *p<0.05.  (B). Cytofluorimetric (FACS) analysis of apoptosis by Annexin V test.  Cells 
were exposed  for 24 h to compound 3 (RC-106) (25 µM). Q1 area represents viable cells; Q2 early-
apoptotic cells; Q3 late-apoptotic cells; Q4  necrotic cells. The images are representative of three 
experiments. (C) WB analysis of apoptotic-related marker after 24 h exposure to 3 (RC-106) at 25 µM. 
Images are representative of two independent experiments.  
 
When the same experiments were repeated under serum-free conditions (Fig. 10), a 
significant increase of apoptotic cells was detected by FACS analysis. In particular,  at 10 
µM, 3 (RC-106) induces significant apoptosis in PaCa3 cells (early apoptotic cells = 10.9 
% ± 0.0 and late apoptotic cells = 17.2 % ± 0.6). The apoptosis induction was further 
confirmed by WB detection of cleaved caspase 3, after exposure of the cells at the same 3 
(RC-106) concentration.  
The apoptotic effect of compound 3 (RC-106) is caspase-dependent, as evidenced by WB 
assay. Therefore, through this functional assay, we can conclude that 3 (RC-106) is a S2R 
agonist. 
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Fig. 10. Apoptosis and apoptotic-related markers analysis in Paca3 cells.  
Paca3 cells were exposed to 24 h starvation-condition and to 10 µM  compound 3 (RC-106) and the 
percentage of apoptotic cells was compared  in  untreated cells (UTR).(A) TUNEL assay: the values are the 
mean±SD of 3 individual experiments. *p<0.05  (B) Representative images of FACS analysis of apoptosis 
by Annexin V test. (C) WB analysis of apoptotic-related markers. Images are representative of two 
independent experiments. 
 
3. Discussion 
On the basis of recent literature evidences, we hypothesized that pan- SR modulators can 
evoke anticancer activity. However, the design of new such compounds represents a 
major challenge, since no structural information is currently available on S2R, which 
could enable the adoption of effective techniques such as e.g., computer-aided drug 
design. Notwithstanding these difficulties, and with this new goal in mind, we capitalized 
our previous work [29c], according to which the presence of a bulky aminic portion 
seemed to be an important feature in favoring ligand binding to both receptors. Therefore, 
we designed a new molecular series of aryl-alkyl(alkenyl) 4-benzylamines. The chemical 
strategy to obtain compounds 1-6, 9 and 11-12 followed a divergent synthesis, based on 
the initial preparation of the common β-aminoketone intermediate A, easily obtainable 
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via Michael chemistry (Scheme 1) [29c]. Accordingly, the smooth bromo-lithium 
exchange on the appropriate aryl bromide afforded the lithiated arene that, upon 
quenching with β-aminoketone A, gave the tertiary alcohols 1-2 in high yields. The 
subsequent dehydration with trifluoroacetic anhydride under Cu(OTf)2 catalysis 
conditions [30] afforded a mixture of olefinic regioisomers C3-C4 and the E stereoisomer 
C2-C3. After purification, olefins 3 and 4 were isolated and finally hydrogenated to 
access the desired amines 5 and 6. The same strategy was applied for accessing 
hydroxylated compounds 9 and 11-12. However, the protection of the aromatic alcohols 
as TBS ethers (and their corresponding removal) was required to avoid interference with 
the lithiation step. Concerning the synthetic pathway of 9 and 11-12, two additional 
observations are worth at this point: i) the lithiation of the protected TBS-bromonaphtols 
with n-BuLi in THF performed better than the t-BuLi/Et2O based method, and ii) keeping 
temperature below -50 °C after quenching with β-aminoketone A improved the efficiency 
of the alcohol synthesis. In the case of racemic compounds, a (semi)preparative chiral 
high performance liquid chromatography (HPLC) resolution process was performed and 
the pure enantiomers obtained in amounts sufficient to support a preliminary biological 
investigation. All compounds showed – in silico and in vitro - very high/good affinity for 
the S1R, with KiS1 values in the range 0.7 – 120 nM (Tables 1, SI1 and SI2, see 
Supplementary material). Molecular modeling revealed that the main molecular 
requirements for high S1R affinity (i.e., the instauration of the prototypical salt bridge 
involving the ligand basic N atom and the carboxylic side chain of Asp126, the 
encasement of an aromatic portion of the ligand within the hydrophobic S1R cavity lined 
by residues Ile128, Phe133, Tyr173 and Leu186, and the generation of a set of further 
stabilizing ligand/receptor π interactions) were all satisfied by the present series of 
compounds.  
Keeping in mind that the purpose of the work was the identification of dual S1R and S2R 
ligands, compounds 3, called by us RC-106, and 6 have been selected for a preliminary 
investigation of their cytotoxic properties, being the molecules in the full series endowed 
with a good affinity towards both receptor subtypes [3 (RC-106) KiS1 = 12.0 ± 5.0 nM; 
KiS2 = 22.0 ± 3.0 nM; 6 KiS1 = 2.1 ± 1.0; KiS2 = 6.5 ± 3.0]. The preliminary biological 
evaluation of 3 (RC-106) and 6 were carried out using PaCa3 cell line (MTS assay) 
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considering the high level of expression of both SRs. For comparative purposes, the 
effects of siramesine (S2R agonist) and NE100 (S1R antagonist) were also evaluated. 
Compounds 3 (RC-106) and siramesine showed an interesting antiproliferative activity, 
both in complete medium and in starvation conditions. Conversely, compound 6 and 
NE100 showed poor cytotoxic properties and therefore 6 were discarded.  
To in depth characterize 3 (RC-106) from a functional point of view, we assessed its S1R 
agonist/antagonist profile on NGF-induced neuronal differentiation in PC12 cells model 
[43]. Indeed, it has been reported that S1R agonists, such as (+)-pentazocine, imipramine, 
fluvoxamine, PRE-084 and RC-33, among the others, potentiate NGF-induced neurite 
outgrowth in PC12 cells, and that selective S1R antagonist (such as NE-100 and 
BD1063) significantly attenuate the efficacy of S1R agonists both in the same in vitro 
assay [29c,43-47]. Our results (Fig. 6) clearly show that compound 3 (RC-106) has a S1R 
antagonist profile.  
We then investigated the cytotoxic activity of 3 (RC-106) on a panel of tumor cell lines 
representative of various cancer types all expressing both SRs.  In particular, with regard 
to S2R, we evaluated PGRMC1 mRNA by RT-PCR as equivalent to S2R expression, 
even if the actual identity of S2R is still controversial [20,40-54]. When we tested the 
effect of 3 (RC-106) on actively proliferating tumor cell lines, we observed significant 
cytotoxicity at concentrations starting from 10 µM in all the cell lines under 
investigation. Interestingly, 3 (RC-106) showed cytotoxic effect in all the cell lines tested 
under low proliferation conditions induced by serum deprivation. In particular, our data 
indicated that a short term starvation (24 hours) enhances the cytotoxic effect of 3 (RC-
106), as evidenced by the low IC50 values detected and by the low dose of 3 (RC-106) 
needed to trigger apoptotic mechanism under these conditions. This result is also in 
agreement with recent data from pre-clinical models showing that short term starvation 
may be able to potentiate the effectiveness of chemotherapy and radiotherapy [55-59]. 
Several clinical trials are currently studying the effect of fasting or fasting-mimic diets in 
patients undergoing chemotherapy (NCT01304251, NCT01175837, NCT00936364, 
NCT01175837, NCT01802346, NCT02126449). Importantly, the apoptotic effect of 3 
(RC-106) is caspase-mediated both in normal and in starvation conditions, evidencing the 
S2R the agonist profile of 3 (RC-106).  
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To sum up, we identified a S1R antagonist and a S2R agonist exerting an interesting 
cytotoxic action toward a panel of tumor cell lines (pancreas, breast, prostate and 
glioblastoma) both in complete medium and under starvation conditions. Our data also 
suggest that the observed decrease of cell viability is due to an apoptotic process 
triggered by 3 (RC-106).   
 
4. Conclusion  
There is increasing evidence that both S1R and S2R play a significant role in cancer 
biology, therefore modulator of both SR subtypes could be of high interest for developing 
novel anti-cancer drugs. In this scenario, we report the design and synthesis of a 
compound series targeting both SR subtypes with high affinity. Among these, we 
identified 3 (RC-106), a compound able to induce a strong cytotoxic effect in a wide 
panel of cancer cell lines, all expressing SRs, both actively proliferating and in low 
proliferation rate in response to serum deprivation. The antitumor properties of 3 (RC-
106) have been observed in all cell lines independently from tumor histotype.  In 
particular, in pancreatic PaCa3 cells, the cell line expressing the highest levels of both 
receptors, 3 (RC-106)  acts as pro-apoptotic drug, inducing a fast triggering of cell death 
program. 
To sum up, 3 (RC-106) exhibited a promising cytotoxic activity on a panel of cancer cell 
lines of different tumors, representative of various cancer expressing both SRs. This 
compound could meet the requirements of new-generation drugs to enter into the so-
called basket trials, consisting in treating several neoplastic diseases, all characterized by 
the same molecular alterations, in this case represented by high expression of S1R or S2R 
or both [60]. Lastly, it has to be underlined that S1R antagonists can be used for 
alleviating chronic pain, especially in conditions such as neuropathic pain, a pathologic 
condition that frequently occurs in cancer patients [61-63]. Accordingly, the 
identification of new, potent pan-sigma receptor modulators will be of great interest, to 
develop antitumor and analgesic drugs, representing an innovative pharmacological 
approach for the treatment of cancer patients with advanced disease. Therefore, 3 (RC-
106) represents the hit compound of a new class of dual-action ligands targeting S1R and 
S2R potentially useful for the treatment of cancer disease. Moreover, the evaluation of 
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the antinociceptive properties of 3 (RC-106) is under investigation and will be reported in 
due course. 
 
5. Experimental section 
5.1. General remarks 
Reagents and solvents for synthesis were obtained from Aldrich (Italy). Solvents were 
purified according to the guidelines in Purification of Laboratory Chemicals. Melting 
points were measured on SMP3 Stuart Scientific apparatus and are uncorrected. 
Analytical thin-layer-chromatography (TLC) was carried out on silica gel precoated 
glass-backed plates (Fluka Kieselgel 60 F254, Merck) and on aluminiumoxid precoated 
aluminium-backed plates (DC-Alufolien Aluminiumoxid 60 F254 neutral, Merck);  
visualized by ultra-violet (UV) radiation, acidic ammonium molybdate (IV), or potassium 
permanganate. Flash chromatography (FC) was performed with Silica Gel 60 (particle 
size 230–400 mesh, purchased from Nova Chimica) and neutral aluminium oxide 
(particle size 0.05-0.15 mm, purchased from Fluka). Proton nuclear magnetic resonance 
(NMR) spectra were recorded on a Bruker Avance 500 spectrometer operating at 500 
MHz. Proton chemical shifts (δ) are reported in ppm with the solvent reference relative to 
tetramethylsilane (TMS) employed as the internal standard (CDCl3, δ = 7.26 ppm). The 
following abbreviations are used to describe spin multiplicity: s = singlet, d = doublet, t = 
triplet, q = quartet, m = multiplet, br = broad signal, dd = doublet-doublet, td = triplet-
doublet. The coupling constant values are reported in Hz. 13C-NMR spectra were 
recorded on a 500 MHz spectrometer, with complete proton decoupling. Carbon chemical 
shifts (δ) are reported in ppm relative to TMS with the respective solvent resonance as 
the internal standard (CDCl3, δ = 77.23 ppm).  
UPLC-UV-ESI/MS analysis were carried out on a Acuity UPLC Waters LCQ FLEET 
system using an ESI source operating in positive ion mode, controlled by ACQUIDITY 
PDA and 4 MICRO (Waters). Analyses were run on a ACQUITY BEH C18 (50 x 2.1 
mm, 1.7 µm) column, at room temperature, with gradient elution (solvent A: water 
containing 0.1% of formic acid; solvent B: methanol containing 0.1% of formic acid; 
gradient: 10% B in A to 100% B in 3 minutes, followed by isocratic elution 100% B for 
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1.5 minutes, return to the initial conditions in 0.2 minutes) at a flow rate of 0.5 mL min-1. 
All of the final compounds had 95% or greater purity. 
Chiral HPLC runs were conducted on a Jasco (Cremella, LC, Italy) HPLC system 
consisting of PU-1580 pump, 851-AS auto-sampler, and MD-1510 Photo Diode Array 
(PDA) detector. Experimental data were acquired and processed by Jasco Borwin PDA 
and Borwin Chromatograph Software. Solvents used for chiral chromatography were 
HPLC grade and supplied by Carlo Erba (Milan, Italy). Chiral analytical columns: 
Chiralcel OJ-H (4.6 mm diameter x 150 mm length, dp 5 µm), Chiralpack IC (4.6 mm 
diameter x 250 mm length, dp 5µm) and Chiralpack IA (4.6 mm diameter x 250 mm 
length, dp 5 µm). Analytes were detected photometrically at 220 and 254 nm. Unless 
otherwise specified, sample solutions were prepared dissolving analytes at 1 mg/mL in 
ethanol and filtered through 0.45 µm PTFE membranes before analysis. The injection 
volume was 10 µL. Detection was performed at 220 and 254 nm. The retention factor 
(k) was calculated using the equation k = (tR - t0)/ t0, where tR is the retention time and 
t0 the dead time (t0 was considered to be equal to the peak of the solvent front and was 
taken from each particular run). The enantioselectivity (α) and the resolution factor (Rs) 
were calculated as follows: α= k2 / k1 and Rs = 2 (tR2 - tR1) / (w1 + w2) where tR2 and tR1 
are the retention times of the second and the first eluted enantiomers, and w1 and w2 are 
the corresponding base peak widths. All HPLC analyses were performed at room 
temperature. 
The best conditions found by the screening protocol were applied to a semi-preparative 
scale-up. The enantiomers of 1, 2, 5 and 9 were then completely resolved by a (semi)-
preparative process using a Chiralcel OJ-H column (10 mm diameter × 250 mm length, 5 
µm), eluting with ethanol (for the compound 2) or methanol (for the compounds 3, 5 and 
8) at RT with a flow rate of 2.5 mL/min. Compounds 6 and 12 were resolved on 
Chiralpak IA (10 mm diameter × 250 mm length, 5 µm) using MeOH at a flow rate of 2.5 
mL/min as eluent. The eluate was fractioned according to the UV profile (detection 
preformed at 220 and 254 nm). The fractions obtained containing the enantiomers were 
evaporated at reduced pressure. Analytical control of collected fractions was performed 
using the analytical columns. 
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Optical rotation values of enantiomeric compounds were measured on a Jasco 
photoelectric polarimeter DIP 1000 using a 0.5 dm cell and a sodium and mercury lamp 
(λ = 589 nm, 435 nm); sample concentration values are given in 10-2g mL-1 (Table 2) 
 
5.2. General procedure for the preparation of compounds 1 and 2 
Under nitrogen atmosphere, tert-BuLi (2.5 equiv, 1.7 M in pentane) was added dropwise 
to a -78 °C cooled solution of the appropriate aryl bromide (1.25 equiv) in anhydrous 
diethyl ether (20 mL). After 20 minutes the reaction was slowly allowed to reach room 
temperature. The stirring was continued for 1 additional hour and a solution of 4-(4-
benzyl-piperidin-1-yl)-butan-2-one (1.0 equiv) in anhydrous diethyl ether (6 mL) was 
then added dropwise at -78 °C. The reaction mixture was slowly warm to 0 °C, stirred for 
3 h and then quenched with water (12 mL); after an acid (pH = 3-4) / base (pH = 8-9) 
work-up, the combined organic phases were evaporated under vacuum to get the desired 
compounds. 
 
5.2.1. 4-(4-benzylpiperidin-1-yl)-2-(naphthalen-2-yl)butan-2-ol, [1]: Yield: 44%; white 
solid; mp: 105-107 °C; IR (cm-1): 3434, 2918, 1653, 1438, 1156, 1112, 820; 1H-NMR 
(500 MHz) (CDCl3) δ (ppm): 8.01 (s, 1H), 7.86-7.81 (m, 3H), 7.47-7.45 (m, 3H), 7.28 (t, 
J = 7.8 Hz, 2H), 7.19 (t, J = 7.0 Hz, 1H), 7.13 (d, J = 7.1 Hz, 2H), 3.19 (d, 1H), 2.54-2.50 
(m, 3H), 2.31 (m, 1H), 2.22-2.14 (m, 2H), 1.92 (d, 1H), 1.84 (m, 1H), 1.76 (m, 1H), 1.68 
(m, 1H), 1.60 (m, 1H), 1.57 (s, 3H), 1.50 (m, 1H), 1.31 (m, 2H); 13C-NMR (500 MHz) 
(CDCl3) δ (ppm): 146.3, 140.5,133.3, 132.0, 129.1, 128.2, 128.1, 127.6, 127.4, 125.8, 
125.4, 123.8, 123.6, 75.7, 55.1, 54.8, 52.6, 43.1, 37.8, 37.4, 32.6, 32.1, 31.4; UHPLC-
ESI-MS: tR = 2.03, > 99.9% pure (λ = 225 nm), m/z = 374 [M + H]+ 
 
5.2.1.1. (+)-4-(4-benzylpiperidin-1-yl)-2-(naphthalen-2-yl)butan-2-ol, [(+)-1]: White 
solid; [α]D20= +40.5 (c 0.2, CH3OH). The IR and NMR spectra are identical to that of 1. 
HPLC: tR = 8.5 min, ee 96.0%. 
5.2.1.2. (-)-4-(4-benzylpiperidin-1-yl)-2-(naphthalen-2-yl)butan-2-ol, [(-)-1]: White 
solid; [α]D20= -42.3 (c 0.2, CH3OH). The IR and NMR spectra are identical to that of 1. 
HPLC: tR = 11.1 min, ee 97.0%. 
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5.2.2. 4-(4-benzylpiperidin-1-yl)-2-phenylbutan-2-ol, [2]: Yield: 77%; white solid; mp: 
90.9-93 °C; IR (cm-1): 3184, 3125, 1602, 1369, 1343, 1156, 846, 699; 1H-NMR (500 
MHz) (CDCl3) δ (ppm): 7.45 (d, J = 8.9 Hz, 2H), 7.33 (t, J = 8.1 Hz, 2H), 7.27 (t, J = 7.4 
Hz, 2H), 7.21-7.19 (m, 2H), 7.13 (d, J = 7.0 Hz, 2H), 3.15 (d, 1H), 2.54 (m, 1H), 2.52 (m, 
2H) 2.30 (m, 1H), 2.22 (m, 1H), 2.07 (m, 1H), 1.86 (m, 1H), 1.80 (m, 1H) 1.75 (m, 1H), 
1.67 (m, 1H) 1.60 (m, 1H), 1.50 (m, 1H), 1.49 (s, 3H) 1.31 (m, 2H); 13C-NMR (500 
MHz) (CDCl3) δ (ppm): 148.9, 140.5, 129.1, 127.9, 128.2, 126.0, 125.8, 125.0, 75.5, 
55.1, 54.8, 52.6, 43.1, 37.8, 37.7, 32.6, 32.1, 31.4; UHPLC-ESI-MS: tR = 1.75, > 97% 
pure (λ = 210 nm),  m/z = 324 [M + H]+ 
 
    
 
5.2.2.1. (+)-4-(4-benzylpiperidin-1-yl)-2-phenylbutan-2-ol, [(+)-2]: Yellow oil; [α]D20= 
+10.5 (c 0.6, CH3OH). The IR and NMR spectra are identical to that of 2. HPLC: tR = 3.4 
min, ee 99.9%. 
 
    
5.2.2.2. (-)-4-(4-benzylpiperidin-1-yl)-2-phenylbutan-2-ol, [(-)-2]: Yellow oil; [α]D20= -
9.2 (c 0.6, CH3OH). The IR and NMR spectra are identical to that of 2. HPLC: tR = 4.2 
min, ee 98.0%. 
 
5.3. General procedure for the preparation of compounds 3 and 4 
Under argon atmosphere trifluoroacetic anhydride (2.0 equiv) was added dropwise to a 
solution of the tertiary alcohol (1.0 equiv) and copper triflate (2 mol %) in anhydrous 
dichloromethane (5 mL) cooled to 0 °C. After stirring the reaction a solution of 
NaHCO3(aq) (5 %) was added. The phases were separated and the organic phase was dried 
over anhydrous Na2SO4 and concentrated under reduced pressure. The obtained crude 
was purified by alumina (II Brockmann degree) column chromatography (9 n-hexane – 1 
ethyl acetate). 
 
5.3.1. (E)-4-benzyl-1-[3-(naphthalen-2-yl)but-2-en-1-yl]piperidine, [3]: Yield: 50%, 
yellow solid; mp: 221-222 °C; IR (cm-1): 3049-2977, 2926, 2848, 2514, 1597, 1482, 
1453-1434, 1287-1157, 1039, 940, 895, 855, 819, 744, 689; 1H-NMR (500 MHz) 
(CDCl3) δ (ppm): 7.82-7.80 (m, 3H). 7.78 (d, J = 9.0 Hz, 1H), 7.61 (d, J = 8.6 Hz, 1H), 
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7.46-7.44 (m, 2H), 7.29 (t, J = 7.4 Hz, 2H), 7.20 (t, J = 7.1 Hz, 1H), 7.16 (d, J = 7.6 Hz, 
2H), 6.09 (t, J = 6.6 Hz, 1H), 3.22 (d, J = 6.5 Hz, 2H), 3.03 (d, 2H) 2.57 (d, J = 6.9 Hz, 2 
H), 2.16 (s, 3H), 1.98 (t, 2H), 1.68 (d, 2H), 1.57 (m, 1H), 1.38 (m, 2 H); 13C-NMR (500 
MHz) (CDCl3) δ (ppm): 140.7, 140.4, 136.9, 133.4, 132.5, 129.1, 128.1, 128.0, 127.6, 
127.5, 126.0, 125.7, 125.6, 124.2, 124.1, 57.2, 54.1, 43.2, 37.9, 32.2, 16.1; UHPLC-ESI-
MS: tR = 2.20, >98% pure (λ = 245 nm),  m/z = 356 [M + H]+ 
 
5.3.2. (E)-4-benzyl-1-(3-phenylbut-2-en-1-yl)piperidine, [4]: Yield: 42%; yellow solid; 
mp: 220-222 °C; IR (cm-1): 3085-2979, 2926, 2488, 1641-1580, 1484-1401, 1273-1160, 
1038, 943, 835, 765-748, 689; 1H-NMR (500 MHz) (CDCl3) δ (ppm): 7.40 (d, J = 7.9, 
2H), 7.31-7.28 (m, 4H); 7.24 (m, 1H), 7.19 (t, J = 7.6 Hz, 1H), 7.15 (d, J = 7.3 Hz, 2H), 
5.92 (t, J = 6.4 Hz, 1H), 3.16 (d, J = 6.5 Hz, 2H), 2.99 (d, 4H), 2.55 (d, J = 6.8 Hz, 2H), 
2.05 (s, 3H), 1.95 (t, 2H), 1.66 (d, 2H), 1.54 (m, 1H), 1.36 (m, 2H); 13C-NMR (500 MHz) 
(CDCl3) δ (ppm): 143.3, 140.7, 137.1, 129.1, 128.2, 128.1, 126.9, 125.7, 125.6, 124.9, 
57.0, 54.0, 43.2, 37.6, 32.1, 16.1; UHPLC-ESI-MS: tR = 1.97, > 98% pure (λ = 205 nm),  
m/z = 306 [M + H]+ 
 
5.4. General procedure for the preparation of compound 5 and 6. 
To a solution of olefin (1.0 equiv) in absolute ethanol (10 mL) was added a catalytic 
amount of Pd (0) / C 10% (p/p, 0.06 equiv). The suspension was stirred vigorously under 
hydrogen atmosphere (1 atm). The reaction mixture was then filtered through Celite, 
using dichloromethane as solvent. The crude was purified by alumina (II Brockmann 
degree) column chromatography (9 n-hexane – 1 ethyl acetate). 
 
5.4.1. 4-benzyl-1-[3-(naphthalen-2-yl)butyl]piperidine, [5]: Yield: 56%, yellow oil; IR 
(cm-1): 3025, 2924, 2508, 1631, 1602, 1542, 1496, 1453; 1H-NMR (500 MHz) (CDCl3) δ 
(ppm): 7.79-7.77 (t, J = 8.7 Hz, 3H), 7.59 (s, 1H), 7.45-7.42 (m, 2H), 7.32 (d, J = 8.8 Hz, 
1H), 7.25 (m, 2H), 7.17 (m, 1H), 7.08 (m, 2H), 3.30 (broad peak, 2H), 2.90 (m, 1H), 2.76 
(m, 1H), 2.55 (d, J = 7.4 Hz, 2H), 2.46 (m, 1H), 2.27-2.13 (m, 4H), 1.82-1.71 (m, 4H), 
1.59 (m, 1H), 1.36 (d, J = 6.5 Hz, 3H); 13C-NMR (500 MHz) (CDCl3) δ (ppm): 142.4, 
139.3, 133.4, 132.3, 128.9, 128.5, 128.3, 127.6, 127.5, 126.1, 125.5, 125.3, 124.8, 56.1, 
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52.4, 41.9, 38.3, 36.5, 31.8, 29.1, 22.7; UHPLC-ESI-MS: tR = 2.17, > 97% pure (λ = 220 
nm), m/z = 358 [M + H]+ 
 
5.4.1.1. (+)-4-benzyl-1-(3-(naphthalen-2-yl)butyl)piperidine, [(+)-5]: Yellow oil; [α]D20= 
+6.1 (c 0.2, CH3OH). The IR and NMR spectra are identical to that of 5. HPLC: tR = 7.7 
min, ee 95.0%. 
5.4.1.2. (-)-4-benzyl-1-(3-(naphthalen-2-yl)butyl)piperidine, [(-)-5]: Yellow oil; [α]D20= -
6.3 (c 0.2, CH3OH). The IR and NMR spectra are identical to that of 5. HPLC: tR = 9.0 
min, ee 95.0%. 
 
5.4.2. 4-benzyl-1-(3-phenylbutyl)piperidine, [6]: Yield: 47%, yellow oil; IR (cm-1): 3682, 
3019, 2929, 2856, 2434, 2400, 1230; 1H-NMR (500 MHz) (CDCl3) δ (ppm): 7.28-7-27 
(m, 4H), 7.17 (m, 4H), 7.13 (d, J = 7.0 Hz, 2H), 2.86 (broad peak, 2H), 2.71 (m, 1H), 
2.52 (d, J = 6.6 Hz, 2H), 2.26 (m, 1H), 2.14 (m, 1H), 1.87-1.72 (m, 4H), 1.61 (d, 2H), 
1.49 (m, 1H), 1.29 (m, 2H), 1.24 (d, J = 7.3 Hz, 3H); 13C-NMR (500 MHz) (CDCl3) δ 
(ppm): 147.3, 140.7, 129.1, 128.3, 128.1, 126.9, 125.9, 125.7, 57.3, 54.1, 53.9, 43.2, 38.4, 
37.9, 35.4, 32.1, 22.6; UHPLC-ESI-MS: tR = 1.92, > 97% pure (λ = 200 nm),  m/z = 308 
[M + H]+ 
 
5.4.2.1. (+)-4-benzyl-1-(3-phenylbutyl)piperidine, [(+)-6]: Yellow oil; [α]D20= +8.2 (c 
0.3, CH3OH). The IR and NMR spectra are identical to that of 6. HPLC: tR = 3.7 min, ee 
99.9%. 
5.4.2.2. (-)-4-benzyl-1-(3-phenylbutyl)piperidine, [(-)-6]: Yellow oil; [α]D20= -8.3 (c 0.3, 
CH3OH). The IR and NMR spectra are identical to that of 6. HPLC: tR = 5.3 min, ee 
99.9%. 
 
 
5.5. (6-bromonaphthalen-2-yloxy)-tert-butyldimethtyl-silane, [7] 
Under argon atmosphere 6-bromo-2-naphthol (1.0 equiv), imidazole (1.0 equiv) and tert-
butyldimethylsilyl chloride (1.2 equiv) were solubilized in anhydrous dimethylformamide 
(20 mL). After stirring the solution overnight, the reaction mixture was extracted by 
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dichloromethane (x 2) and brine (x 5). The organic phase was dried over Na2SO4, and 
concentrated under reduced pressure. The crude was purified by column chromatography 
(10 n-hexane). 
 
Yield: 90%, white solid; mp: 62-64 °C; IR (cm-1): 3743, 2954, 1735, 1653, 1560, 1470, 
1256, 1062; 1H-NMR (500 MHz) (CDCl3) δ (ppm): 7.92 (s, 1H), 7.64 (d, J = 8.9 Hz, 
1H), 7.57 (d, J = 8.9 Hz, 1H), 7.48 (dd, J = 9.2 and 2.3 Hz, 1H), 7.16 (ds, J = 2.4 Hz, 
1H), 7.10 (dd, J = 8.5 and 2.2 Hz, 1H), 1.02 (s, 9H), 0.25 (s, 6H); 13C-NMR (500 MHz) 
(CDCl3) δ (ppm): 153.8, 133.1, 130.2, 129.6, 129.4, 128.4, 128.3, 123.1, 117.3, 114.9, 
25.7, 18.2, -4.4; ESI-MS: m/z = 338 [M + H]+ 
 
5.6. 4-(4-benzylpiperidin-1-yl)-2-[6-(tert-butyldimethyl-silanoloxy)-naphtalen-2-yl]-
butan-2-ol, [8] 
Compound 7 (1.5 equiv) was dissolved in anhydrous tetrahydrofuran (5 mL) under argon 
atmosphere. The solution was cooled to -78 °C, then was added dropwise n-butyl-lithium 
(4.4 equiv, 2.5 M in n-hexane). After 20 minutes, the temperature was increased up to -50 
°C and a solution of 4-(4-benzyl-piperidin-1-yl)-butan-2-one (1.0 equiv) in anhydrous 
tetrahydrofuran (5.0 mL) was added dropwise. The reaction mixture was stirred for 1.5 h, 
keeping the temperature below -50 °C. The solution was quenched with 10 mL of 
saturated solution of NH4Cl(aq) and extracted with Et2O. The organic phase was dried 
over Na2SO4. The solvent was removed under reduced pressure and the crude was 
purified by alumina (II Brockmann degree) column chromatography (8 n-hexane – 2 
ethyl acetate). 
 
Yield: 63%; bright yellow oil; IR (cm-1): 3336, 3026, 2926, 2856, 2349, 2310, 1603, 
1496, 1471, 1453, 1371, 1260; 1H-NMR (500 MHz) (CDCl3) δ (ppm): 7.92 (s, 1H), 7.72 
(d, J = 9.1 Hz, 1H), 7.65 (d, J = 8.6 Hz, 1H), 7.42 (d, J = 8.6 Hz, 1H), 7.27 (m, 2H), 7.18 
(t, J = 7.7 Hz, 2H), 7.12 (t, J = 8.6 Hz, 2H), 7.06 (dd, J = 8.4 and 1.8 Hz, 1H), 3.18 
(broad peak, 1H), 3.02 (broad peak, 1H), 2.61 (broad peak, 1H), 2.53 (m, 2H), 2.31 (d, 
1H), 2.12 (t, 1H), 1.92-1.86 (m, 2H), 1.75 (m, 1H), 1.65-1.63 (m, 2H), 1.54 (s, 3H), 1.51 
(m, 1H), 1.29 (m, 2H), 1.02 (s, 9H), 0.24 (s, 6H); 13C-NMR (500 MHz) (CDCl3) δ (ppm): 
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153.2, 144.2, 140.5, 133.1, 129.4, 129.1, 129.0, 128.2, 126.4, 125.8, 124.1, 123.3, 122.0, 
114.5, 75.6, 55.1, 54.7, 54.2, 53.7, 52.6, 43.1, 37.8, 37.4, 32.5, 32.1, 31.4, 25.7, 18.2, -
4.3; APCI-MS: m/z = 504 [M + H]+ 
 
5.7. (E)-4-benzyl-1-{3-[6-(tert-butyldimethyl-silanyloxy)-naphthalen-2-yl]-but-2-en-1-
yl}-piperidine, [10].  
Under argon atmosphere trifluoroacetic anhydride (2.0 equiv) was added dropwise to a 
solution of compound 8 (1.0 equiv) and copper triflate (2 mol %) in anhydrous 
dichloromethane (5 mL) cooled to 0 °C. After stirring the reaction a solution of 
NaHCO3(aq) (5 %) was added. The phases were separated and the organic phase was dried 
over anhydrous Na2SO4 and concentrated under reduced pressure. The obtained crude 
was purified by alumina (II Brockmann degree) column chromatography (9 n-hexane – 1 
ethyl acetate). 
 
Yield: 61%; yellow solid; mp: 102-104 °C; IR (cm-1): 3027, 2926, 2856, 2801, 2349, 
1597, 1497, 1478, 1374, 1318, 1257; 1H-NMR (500 MHz) (CDCl3) δ (ppm): 7.74 (s, 1H), 
7.69 (d, J = 9.0 Hz, 1H), 7.63 (d, J = 8.9 Hz, 1H), 7.56 (d, J = 8.7 Hz, 1H), 7.28 (m, 2H), 
7.19-7.15 (m, 4H), 7.06 (d, J = 9.1 Hz, 1H), 6.04 (t, J = 6.7 Hz, 1H), 3.21 (d, 2H), 3.02 
(broad peak, 2H), 2.56 (d, J = 7.0 Hz, 2H), 2.13 (s, 3H), 1.97 (broad peak, 2H), 1.68 
(broad peak, 2H), 1.55 (broad peak, 1H), 1.36 (m, 2H), 1.02 (s, 9H), 0.25 (s, 6H); 13C-
NMR (500 MHz) (CDCl3) δ (ppm): 153.4, 140.7, 138.5, 136.9, 133.7, 129.4, 129.1, 
128.1, 126.4, 125.7, 125.0, 124.5, 123.9, 122.2, 114.7, 57.2, 54.1, 43.2, 37.9, 32.2, 25.7, 
18.2, 16.1, -4.4; ESI-MS: m/z = 486 [M + H]+ 
 
5.8. General procedure for the preparation of compounds 9 and 11 
Tetra-N-butylammonium fluoride (1.5 equiv, 1.0 M in tetrehydrofuran) was added 
dropwise to a solution of compounds 8 and 10 (1.0 equiv) in anhydrous dichloromethane 
(5.0 mL), at 0 °C, in argon atmosphere. After 2 h the reaction mixture was extracted by a 
solution of NaHCO3 (5%). In the case of compound 9, the crude was purified by column 
chromatography (9 dichloromethane – 1 methanol – 0.1% NH3 in methanol); on the 
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contrary for compound 11, it was been enough to do a precipitation of the solid impurities 
using methanol. 
 
5.8.1. 6-[4-(4-benzylpiperidin-1-yl)-2-hydroxybutan-2-yl]naphthalen-2-ol, [9]: Yield: 
64%; yellow oil; IR (cm-1): 3452, 2925, 1633, 1605, 1560, 1454, 1381; 1H-NMR (500 
MHz) (CDCl3) δ (ppm):  7.91 (s, 1H), 7.72 (d, J = 8.4 Hz, 1H), 7.60 (d, J = 8.4 Hz, 1H), 
7.40 (d, J = 8.8 Hz, 1H), 7.25 (t, J = 6.9 Hz, 2H), 7.18-7.14 (m, 3H), 7.07 (d, J = 8.0 Hz, 
2H), 3.20 (broad peak, 1H), 2.61 (broad peak, 1H), 2.46 (d, J = 6.5 Hz, 2H), 2.34 (m, 
2H), 2.18 (m, 1H), 1.96 (broad peak, 1H), 1.88 (broad peak, 1H), 1.80 (broad peak, 1H), 
1.66 (broad peak, 2H), 1.59 (s, 1H), 1.49 (broad peak, 1H), 1.34 (broad peak, 2H); 13C-
NMR (500 MHz) (CDCl3) δ (ppm): 154.0, 143.0, 140.3, 133.3, 129.8, 129.0, 128.5, 
128.2, 126.2, 125.8, 124.1, 123.4, 118.3, 109.2, 75.8, 55.0, 54.7, 52.6, 42.9, 37.6, 37.4, 
31.7, 31.3; UHPLC-ESI-MS: tR = 1.68, > 97% pure (λ = 230 nm),  m/z = 390 [M + H]+ 
 
5.8.1.1. (+)-6-[4-(4-benzylpiperidin-1-yl)-2-hydroxybutan-2-yl]naphthalen-2-ol, [(+)-9]: 
Yellow oil; [α]D20= +24.2 (c 0.1, CH3OH). The IR and NMR spectra are identical to that 
of 9. HPLC: tR = 4.0 min, ee 99.9%. 
5.8.1.2. (-)-6-[4-(4-benzylpiperidin-1-yl)-2-hydroxybutan-2-yl]naphthalen-2-ol, [(-)-9]: 
Yellow oil; [α]D20= -24.8 (c 0.1, CH3OH). The IR and NMR spectra are identical to that 
of 9. HPLC: tR = 5.0 min, ee 99.9%. 
 
5.8.2. (E)-6-[4-(4-benzylpiperidin-1-yl)but-2-en-2-yl]naphthalen-2-ol, [11]: Yield: 64%; 
bright yellow solid; mp: 157-159 °C; IR (cm-1): 3629, 2926, 2854,2349, 1601, 1454; 1H-
NMR (500 MHz) (CDCl3) δ (ppm): 7.50 (s, 1H), 7.44 (d, J = 8.7 Hz, 1H), 7.28 (t, J = 8.1 
Hz, 2H), 7.19 (t, J = 8.0 Hz, 1H), 7.15-7.11 (t, J = 7.8 Hz, 2H), 7.03-7.01 (m, 3H), 6.89 
(ds, 1H), 5.89 (t, J = 7.2 Hz, 1H), 3.28 (ds, 2H), 3.21 (ds, 2H), 2.57 (d, J = 7.5 Hz, 2H), 
2.13 (m, 2H), 2.12 (s, 3H), 1.74 (m, 2H), 1.63 (m, 1H), 1.53 (m, 2H); 13C-NMR (500 
MHz) (CDCl3) δ (ppm): 154.5, 140.4, 136.7, 134.0, 130.0, 129.1, 128.2, 128.0, 125.9, 
124.0, 123.7, 122.7, 119.2, 109.9, 56.8, 53.9, 42.9, 37.8, 31.3, 15.7; UHPLC-ESI-MS: tR 
= 1.92, > 97% pure (λ = 245 nm),  m/z = 372 [M + H]+ 
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5.9. 6-[4-(4-benzylpiperidin-1-yl)butan-2-yl]naphthalen-2-ol, [12]:  
To a solution of compound 11 (1.0 equiv) in absolute ethanol (10 mL) was added a 
catalytic amount of Pd (0) / C 10% (p/p, 0.06 equiv). The suspension was stirred 
vigorously under hydrogen atmosphere (1 atm). The reaction mixture was then filtered 
through Celite, using dichloromethane as solvent. The crude was purified by column 
chromatography (9 dichloromethane – 1 methanol – 0.1% NH3 in methanol). 
 
Yield: 39%; yellow oil; IR (cm-1): 3297, 2924, 2349, 2309, 1604, 1453, 1376, 1269; 1H-
NMR (500 MHz) (CDCl3) δ (ppm): 7.42 (d, J = 9.0 Hz, 1H), 7.37 (s, 1H), 7.24 (t, 2H), 
7.17 (d, J = 8.0 Hz, 1H), 7.17 (m, 1H), 7.06 (m, 3H), 6.98 (d, J = 9.0 Hz, 1H), 6.81 (s, 
1H), 3.26 (broad peak, 1H), 3.10 (broad peak, 1H), 2.73 (m, 1H), 2.50-2.49 (broad peak, 
4H), 2.14-2.12 (m, 2H), 2.04 (m, 2H), 1.67 (m, 2H), 1.60-1.54 (m, 3H), 1.28 (overlapped 
peak, 3H); 13C-NMR (500 MHz) (CDCl3) δ (ppm): 154.6, 139.5, 133.6, 129.0, 128.3, 
126.8, 126.0, 125.1, 125.0, 118.7, 109.2, 56.5, 53.7, 52.9, 42.3, 38.1, 37.0, 33.2, 30.0, 
22.9; UHPLC-ESI-MS: tR = 1.86, > 95% pure (λ = 230 nm), m/z = 374 [M + H]+ 
 
5.9.1. (+)-6-[4-(4-benzylpiperidin-1-yl)butan-2-yl]naphthalen-2-ol, [(+)-12]: Yellow oil; 
[α]D20= +11.8 (c 0.3, CH3OH). The IR and NMR spectra are identical to that of 12. 
HPLC: tR = 4.9 min, ee 99.9%. 
5.9.2. (-)-6-[4-(4-benzylpiperidin-1-yl)butan-2-yl]naphthalen-2-ol, [(-)-12]: Yellow oil; 
[α]D20= -12.0 (c 0.3, CH3OH). The IR and NMR spectra are identical to that of 12. HPLC: 
tR = 5.7 min, ee 99.9%. 
 
5.10. Molecular modeling 
The optimized structures of selected compounds were docked into the putative binding 
pockets for the S1R by applying a consolidated procedure [29d,31a,32-35,64]. The 
resulting docked conformations for each complex were clustered and visualized; then, for 
each compound, only the molecular conformation satisfying the combined criteria of 
having the lowest (i.e., more favorable) energy and belonging to a highly populated 
cluster was selected to carry for further modeling. The ligand/receptor complexes 
obtained from the docking procedure was further refined in Amber 14 [65] using the 
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quenched molecular dynamics (QMD) method, as previously described [29d,31a,32-
35,64]. According to QMD, the best energy configuration of each complex resulting from 
this step was subsequently solvated by a cubic box of TIP3P [66] water molecules 
extending at least 10 Å in each direction from the solute. The system was neutralized and 
the solution ionic strength was adjusted to the physiological value of 0.15 M by adding 
the required amounts of Na+ and Cl- ions. Each solvated system was relaxed by 500 steps 
of steepest descent followed by 500 other conjugate-gradient minimization steps and then 
gradually heated to a target temperature of 300 K in intervals of 50 ps of NVT MD, using 
a Verlet integration time step of 1.0 fs. The Langevin thermostat was used to control 
temperature, with a collision frequency of 2.0 ps-1 The protein was restrained with a force 
constant of 2.0 kcal/(mol Å), and all simulations were carried out with periodic boundary 
conditions. Subsequently, the density of the system was equilibrated via MD runs in the 
isothermal-isobaric (NPT) ensemble, with isotropic position scaling and a pressure 
relaxation time of 1.0 ps for 50 ps with a time step of 1 fs. All restraints on the protein 
atoms were then removed, and each system was further equilibrated using NPT MD runs 
at 300 K, with a pressure relaxation time of 2.0 ps. Three equilibration steps were 
performed, each 2 ns long and with a time step of 2.0 fs. To check the system stability, 
the fluctuations of the rmsd of the simulated position of the backbone atoms of the 
receptor with respect to those of the initial protein were monitored. All chemophysical 
parameters and rmsd values showed very low fluctuations at the end of the equilibration 
process, indicating that the systems reached a true equilibrium condition. The 
equilibration phase was followed by a data production run consisting of 40 ns of MD 
simulations in the canonical (NVT) ensemble. Only the last 20 ns of each equilibrated 
MD trajectory were considered for statistical data collections. A total of 1000 trajectory 
snapshots were analyzed the each ligand/receptor complex. The binding free energy, 
∆Gbind, between the ligands and the sigma1 receptor was estimated by resorting to the 
MM/PBSA approach implemented in Amber 14. According to this well validated 
methodology [36], the free energy was calculated for each molecular species (complex, 
receptor, and ligand), and the binding free energy was computed as the difference: 
∆Gbind = Gcomplex – (Greceptor + Gligand) = ∆EMM + ∆Gsol - T∆S 
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in which ∆EMM represents the molecular mechanics energy, ∆Gsol includes the solvation 
free energy and T∆S is the conformational entropy upon ligand binding. The per residue 
decomposition of the enthalpic term of ∆Gbind was performed exploiting the equilibrated 
MD trajectory of each given compound/receptor complex. This analysis was carried out 
using the MM/GBSA approach [67,68], and was based on the same snapshots used in the 
binding free energy calculation. All simulations were carried out using the Pmemd 
modules of Amber 14, running on the MOSE CPU/GPU calculation cluster.  
 
5.11. Binding assays 
5.11.1. Materials  
Guinea pig brains for the S1R binding assays were commercially available (Harlan–
Winkelmann, Borchen, Germany). Homogenizer: Elvehjem Potter (B. Braun Biotech 
International, Melsungen, Germany) and Soniprep 150, MSE, London, UK). Centrifuges: 
Cooling centrifuge model Rotina 35R (Hettich, Tuttlingen, Germany) and High-speed 
cooling centrifuge model Sorvall RC-5C plus (Thermo Fisher Scientific, Langenselbold, 
Germany). Multiplates: standard 96-well multiplates (Diagonal, Muenster, Germany). 
Shaker: self-made device with adjustable temperature and tumbling speed (scientific 
workshop of the institute). Vortexer: Vortex Genie 2 (Thermo Fisher Scientific, 
Langenselbold, Germany). Harvester: MicroBeta FilterMate-96 Harvester. Filter: Printed 
Filtermat Type A and B. Scintillator: Meltilex (Type A or B) solid-state scintillator. 
Scintillation analyzer: MicroBeta Trilux (all PerkinElmer LAS, Rodgau-Jügesheim, 
Germany). Chemicals and reagents were purchased from various commercial sources and 
were of analytical grade. 
 
5.11.2. Preparation of membrane homogenates from guinea pig brain cortex 
Five guinea pig brains were homogenized with the potter (500–800 rpm, 10 up-and-down 
strokes) in six volumes of cold 0.32m sucrose. The suspension was centrifuged at 1200 g 
for 10 min at 4°C. The supernatant was separated and centrifuged at 23500 g for 20 min 
at 4°C. The pellet was resuspended in 5–6 volumes of buffer (50 mm Tris, pH 7.4) and 
centrifuged again at 23500 g (20 min, 4 8C). This procedure was repeated twice. The 
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final pellet was resuspended in 5–6 volumes of buffer and frozen (-80°C) in 1.5 mL 
portions containing ~1.5 (mg protein)mL-1. 
 
5.11.3. Protein determination 
The protein concentration was determined by the method of BradfordS2 modified by 
Stoscheck.S3 The Bradford solution was prepared by dissolving 5 mg of Coomassie 
Brilliant Blue G 250 in 2.5 mL EtOH (95% v/v). Deionized H2O (10 mL) and phosphoric 
acid (85% w/v, 5 mL) were added to this solution, and the mixture was stirred and filled 
to a total volume of 50 mL with deionized water. Calibration was carried out using 
bovine serum albumin as a standard in nine concentrations (0.1, 0.2, 0.4, 0.6, 0.8, 1.0, 
1.5, 2.0, and 4.0 mg mL-1). In a 96-well standard multiplate, 10 mL of the calibration 
solution or 10 mL of the membrane receptor preparation were mixed with 190 mL of the 
Bradford solution. After 5 min, the UV absorption of the protein–dye complex at l=595 
nm was measured with a plate reader (Tecan Genios, Tecan, Crailsheim, Germany). 
 
5.11.4. General protocol for binding assays 
The test compound solutions were prepared by dissolving ~10 mmol (usually 2–4 mg) of 
test compound in DMSO so that a 10 µM stock solution was obtained. To obtain the 
required test solutions for the assay, the DMSO stock solution was diluted with the 
respective assay buffer. The filtermats were presoaked in 0.5% aqueous polyethylenimine 
solution for 2 h at RT before use. All binding experiments were carried out in duplicate in 
96-well multiplates. The concentrations given are the final concentrations in the assay. 
Generally, the assays were performed by addition of 50 µL of the respective assay buffer, 
50 µL test compound solution at various concentrations (10-5, 10-6, 10-7, 10-8, 10-9 and 10-
10M), 50 µL of corresponding radioligand solution, and 50 µL of the respective receptor 
preparation into each well of the multiplate (total volume 200 µL). The receptor 
preparation was always added last. During the incubation, the multiplates were shaken at 
a speed of 500–600 rpm at the specified temperature. Unless otherwise noted, the assays 
were terminated after 120 min by rapid filtration using the harvester. During the filtration 
each well was washed five times with 300 mL of water. Subsequently, the filtermats were 
dried at 95°C. The solid scintillator was melted on the dried filtermats at 95°C for 5 min. 
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After solidifying of the scintillator at RT, the trapped radioactivity in the filtermats was 
measured with the scintillation analyzer. Each position on the filtermat corresponding to 
one well of the multiplate was measured for 5 min with the [3H]-counting protocol. The 
overall counting efficiency was 20%. The IC50 values were calculated with GraphPad 
Prism 3.0 (GraphPad Software, San Diego, CA, USA) by nonlinear regression analysis. 
The IC50 values were subsequently transformed into Ki values using the equation of 
Cheng and Prusoff. The Ki values are given as mean value ±SEM from three independent 
experiments.  
 
5.11.5. S1R binding assay 
The assay was performed with the radioligand [3H](+)-pentazocine (22.0 Ci mmol-1; 
PerkinElmer). The thawed membrane preparation of guinea pig brain cortex (~100 mg 
protein) was incubated with various concentrations of test compounds, 2 nM [3H](+)-
pentazocine, and Tris buffer (50 mM, pH 7.4) at 37°C. The nonspecific binding was 
determined with 10 mM unlabeled (+)-pentazocine. The Kd value of (+)-pentazocine is 
2.9 nM. 
 
5.11.6. S2R binding assay 
The assay was performed using 150 µg of rat liver homogenate were incubated for 120 
min at room temperature with 3 nM [3H]-DTG (Perkin–Elmer, specific activity 58.1 Ci  
mmol-1) in 50 mM Tris–HCl, pH 8.0, 0.5 mL final volume. (+)-pentazocine (100 nM) and 
haloperidol (10 µM) were used to mask S1R and to define non-specific binding, 
respectively. 
 
5.12. Cell lines 
PC12 cells were grown in RPMI 1640 (Mediatech, Manassas, VA) supplemented with 
10% heat inactivated horse serum (HS) and 5% fetal bovine serum (FBS) (Biochrom) 1% 
Glutamax, 1% penicillin/streptomycin (pen/strep). Cell differentiation was induced by 
exposure to a medium containing RPMI 1640 supplemented with 0.5% HS, Glutamax 
1%, pen/strep 1% and NGF 2.5ng/ml. PRE-084 and BD-1063 were prepared at 10 mM 
stock solutions in apyrogenic water.  Pancreatic adenocarcinoma Capan-2 and PaCa3, 
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breast adenocarcinoma MDA-MB 231 and SUM 159 cell line and prostatic 
adenocarcinoma PC3 cell lines were grown in culture medium composed of 
DMEM/Ham’s F12 (1:1) (Euroclone) supplemented with fetal calf serum (FCS) (10%) 
(Euroclone), glutamine (2 mM) (Euroclone) and insulin (10 µg/ml) (Sigma-Aldrich, St. 
Louis, MO, USA).  Glioblastoma cell line U87 was grown in EMEM culture medium 
(Euroclone) supplemented with FCS (10%) and glutamine (2mM).  Prostatic 
adenocarcinoma cell line LNCaP was grown in RPMI culture medium (Euroclone) 
supplemented with FCS (10%) and glutamine (2mM).  Serum restriction was done by 
incubating cells in low glucose culture medium without FCS for 24 h. All cell lines were 
purchased by the American Type Culture Collection (ATCC) except for SUM 159 that 
was purchased from Amsterand plc (Detroit, MI, USA).  
All experiments were performed on cells in the exponential growth phase and checked 
periodically for mycoplasma contamination by MycoAlert™ Mycoplasma Detection Kit 
(Lonza, Basel, Switzerland). 
 
5.13. Cytotoxicity test 
5.13.1. MTS Assay 
CellTiter 96® AQueous One Solution Cell Proliferation Assay (Promega, Milan, Italy) 
was used on cells seeded onto a 96-well plate at a density of 3 × 103 cells per well. The 
effect of the drugs was evaluated after 24 h of continued exposure. Three independent 
experiments were performed in octuplicate. The optical density (OD) of treated and 
untreated cells was determined at a wavelength of 490 nm using a plate reader. Dose 
response curves were created by Excel software. IC50 values were determined graphically 
from the plot. 
 
5.13.2. Flow Cytometry 
Flow cytometric analysis was performed using a FACS Canto flow cytometer (Becton 
Dickinson, San Diego, CA). Data acquisition and analysis were performed using 
FACSDiva software (Becton Dickinson). Samples were run in triplicate and 10,000 
events were collected for each replicate. 
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5.13.3. Annexin-V assay 
After exposure to compound, medium was removed and cell were detached by 
tripsinization, washed once in PBS 1X and incubated with 25µl/ml Annexin V-FITC in 
binding buffer (Affimetrix eBioscience, San Diego, USA) for 15 min at 37°C in a 
humidified atmosphere in the dark. Cells were then washed in PBS and suspended in 
binding buffer. 
Immediately before flow cytometric analysis, propidium iodide was added to a final 
concentration of 5 µg/ml to discriminate between apoptotic (Ann-V positive and PI 
positive or PI negative) and necrotic cells (Ann-V negative and PI positive). 
 
5.13.4. TUNEL assay 
Cells were fixed in 1% formaldehyde in PBS on ice for 15 min, suspended in 70% ice 
cold ethanol and stored overnight at 20°C. Cells were then washed twice in PBS and re-
suspended in PBS containing 0.1% Triton X-100 for 5 min at 48C. Thereafter, samples 
were incubated in 50µl of solution containing TdT and FITC conjugated dUTP 
deoxynucleotides 1:1 (Roche Diagnostic GmbH, Mannheim, Germany) in a humidified 
atmosphere for 90 min at 37°C in the dark, washed in PBS, counterstained with 
propidium iodide (2.5 µg/ml, MP Biomedicals, Verona, Italy) and RNAse (10 kU/ml, 
Sigma–Aldrich) for 30 min at 48°C in the dark and analyzed by flow cytometry. 
 
5.13.5. Western blot  
Cell proteins were extracted with M-PER Mammalian Protein Extraction Reagent 
(Thermo Fisher Scientific) supplemented with Halt Protease Phosphatase Inhibitor 
Cocktail (Thermo Fisher Scientific). Mini-PROTEANTGX™ precast gels (4–20%) 
(BIO-RAD) were run using Mini-PROTEAN Tetra electrophoresis cells and then 
electroblotted by Trans-BlotTurbo™ Mini PVDF Transfer Packs (BIORAD). The 
unoccupied membrane sites were blocked with T-TBS 1X (Tween 0.1%) and 5% non-fat 
dry milk to prevent nonspecific binding of antibodies and probed with specific primary 
antibodies overnight at 4 °C. This was followed by incubation with the respective 
secondary antibodies. The antibody-antigen complexes were detected with Immun-Star™ 
WesternC™ kit (BIO-RAD). 
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The following primary antibodies were used: anti-caspase-3 (Cell Signaling Technology, 
Inc., Celbio, Pero, Milan, Italy). Ant-vinculin (sc-5573) from Santa Cruz Biotechnology 
was used as housekeeping. Quantity One Software was used for analysis 
 
5.14. Real time RT-PCR 
Total cellular RNA was extracted using TRIzol reagent (Life technologies) in accordance 
with manufacturer’s instruction and quantified using the Nanodrop MD-1000 
spectrophotometer system. Reverse transcription reactions were performed in 20 µL of 
nuclease free water containing 400 ng of total RNA using iScript cDNA Synthesis kit 
(Bio-Rad Laboratories, Hercules, CA). Real-Time PCR was run using 7500 Fast Real-
Time PCR system (Applied Biosystems) and TaqMan assays to detect the expression of 
SIGMAR1 and PGRMC1 genes.  
Reactions were carried out in triplicate at a final volume of 20 µL containing 40 ng of 
cDNA template, TaqMan universal PCR Master Mix (2X), and selected TaqMan assays 
(20X). Samples were maintained at 50°C for 2 minutes, then at 95°C for 10 minutes 
followed by 40 amplification cycles at 95°C for 15 seconds, and at 60°C for 30 seconds.  
The amount of mRNA was normalized to the endogenous genes GAPDH and HPRT-1. 
 
5.15. Statistical analysis 
All statistical analyses were done using standard software packages GraphPad Prism 
(GraphPad Software, San Diego California USA, version 5.0). The comparison between 
groups was performed by applying the Student "t" test  for 2-group comparisons or one-
way ANOVA followed by appropriate post hoc tests for multiple comparisons. p-values 
lower than 0.05 were considered statistically significant. 
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Highlights 
• Design, synthesis and binding affinity evaluation of racemic and entiomeric pan-Sigma 
Receptor (SR) modulators. 
• S1R agonist/antagonist profile  
• Cytotoxic activity toward a panel of cancer cell lines. 
• Compound 3 (RC-106) highlighted a promising cytotoxic activity on a panel of cancer cell 
lines of different tumors, representative of various cancer expressing both SRs. 
 
 
